Reckitt Benckiser Group plc (RBGLY)
| Market Cap | 43.36B -6.4% |
| Revenue (ttm) | 19.12B -0.9% |
| Net Income | 4.28B +106.1% |
| EPS | 6.55 +116.1% |
| Shares Out | n/a |
| PE Ratio | 10.12 |
| Forward PE | 15.19 |
| Dividend | 1.12 (8.01%) |
| Ex-Dividend Date | Apr 10, 2026 |
| Volume | 476,042 |
| Open | 13.67 |
| Previous Close | 13.36 |
| Day's Range | 13.66 - 14.05 |
| 52-Week Range | 12.02 - 17.80 |
| Beta | 0.25 |
| Analysts | Buy |
| Price Target | 16.53 (+18.16%) |
| Earnings Date | Jul 29, 2026 |
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under... [Read more]
Financial Performance
In 2025, Reckitt Benckiser Group's revenue was 14.21 billion, an increase of 0.25% compared to the previous year's 14.17 billion. Earnings were 3.18 billion, an increase of 123.14%.
Financial numbers in GBP Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for RBGLY stock is "Buy." The 12-month stock price target is $16.53, which is an increase of 18.16% from the latest price.
News
Missouri jury sides with Enfamil maker Mead Johnson in case over preterm baby formula
A jury in St. Louis on Thursday rejected claims that Reckitt unit Mead Johnson's specialized formula for preterm babies was to blame for causing an infant's dangerous bowel disease.
Reckitt Benckiser Group Transcript: Investor update
Digital science and AI are transforming all stages of innovation, driving faster, larger, and more successful product launches, with tangible impacts on growth, cost savings, and sustainability. Proprietary data, advanced platforms, and a global upskilling effort underpin a robust, differentiated pipeline and operational efficiency.
Reckitt stock dips on Q1 miss: what's really ailing the health giant?
Reckitt stock fell about 5% in early trading on Wednesday after the consumer goods group said first-quarter core like-for-like net revenue rose only 1.3%. The figure was well below the 2.9% analysts h...
Reckitt Benckiser Group Earnings Call Transcript: Q1 2026
Core Reckitt delivered 1.3% like-for-like net revenue growth in Q1, with 3.1% growth excluding seasonal business, led by strong performance in China and India. Full-year guidance for 4%-5% growth and higher margins is maintained, despite ongoing geopolitical and input cost headwinds.
Reckitt Benckiser Group Quarterly report: Q1 2026
Reckitt Benckiser Group has published its Q1 2026 quarterly earnings report on April 22, 2026.
Reckitt's Like-for-Like Revenue Rises on Emerging Markets Performance
Lysol maker Reckitt Benckiser booked a rise in first-quarter like for like revenue, helped by strong emerging markets performance, where like-for-like sales grew 7.6%.
Reckitt misses revenue forecast, warns on margins on oil price shock
Reckitt missed quarterly like-for-like revenue forecasts and warned of lower first-half margins, citing high oil prices and a weak cold and flu season, knocking the Dettol maker's shares as much as 7...
Reckitt Benckiser Group Transcript: UBS Global Consumer and Retail Conference
Emerging markets, especially China, drove significant growth through focused leadership and digital innovation, while mature markets like Europe face flat growth and North America is set for recovery in 2026. Margin expansion is targeted via operational efficiencies, portfolio transformation, and increased R&D and AI investments.
Reckitt Benckiser Group Earnings Call Transcript: Q4 2025
Core net revenue grew 5.2% year-over-year, led by double-digit gains in emerging markets, while adjusted operating profit and margins improved. Portfolio focus, innovation, and supply chain investments supported growth, with strong cash returns to shareholders and a positive outlook for 2026.
Reckitt Benckiser Group Annual report: Q4 2025
Reckitt Benckiser Group has published its Q4 2025 annual report on March 5, 2026.
Reckitt Benckiser Group Annual report: Q4 2025
Reckitt Benckiser Group has published its Q4 2025 annual report on March 5, 2026.
Reckitt Benckiser Group Slides: Q4 2025
Reckitt Benckiser Group has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 5, 2026.
Lysol Maker Reckitt Books Rise in Revenue, Boosted by Emerging Markets
The Lysol disinfectant maker's sales grew 5% on a like-for-like basis on year, Reckitt Benckiser said.
Reckitt Benckiser Group Transcript: Consumer Analyst Group of New York Conference (CAGNY) 2026
Sharpened focus on core Powerbrands and emerging markets is driving accelerated growth, with innovation and digital transformation fueling category expansion and operational efficiency. Sustained high margins, disciplined capital allocation, and a robust pipeline support confidence in 4%-5% annual growth and durable EPS gains.
Reckitt Benckiser Group Slides: FY 2026
Reckitt Benckiser Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on February 19, 2026.
Avatars, influencers in China livestreams help drive Reckitt's emerging-market led growth
Influencers and AI-generated avatars selling everything from Durex condoms to Harpic toilet cleaner on livestreaming apps in China are propelling emerging-market led growth for consumer goods company ...
Reckitt Benckiser Group Transcript: Status Update
Emerging Markets are delivering high single-digit growth, driven by strong brands, local execution, and expansion into new categories and geographies. Gross margins are rising due to premiumization, and the business is leveraging digital, offline, and OTC excellence to sustain growth and value creation.
Reckitt Benckiser Group Press release: Status Update
Reckitt Benckiser Group issued a press release on December 4, 2025, disclosing material business information to investors.
Reckitt Benckiser Logs Higher Sales as Consumers Spend on Self-Care
Sales grew 7% on a like-for-like basis, lifted by consumer spending on self-care, germ-protection and sexual-health products.
Reckitt Benckiser Group Earnings Call Transcript: Q3 2025
Q3 saw 7% like-for-like net revenue growth, led by emerging markets and strong innovation, with China delivering nine consecutive quarters of double-digit growth. Guidance for 2025 is maintained, with developed markets expected to remain challenging and emerging markets to drive outsized growth.
Reckitt Benckiser Group Earnings release: Q3 2025
Reckitt Benckiser Group released its Q3 2025 earnings on October 22, 2025, summarizing the period's financial results.
Reckitt Benckiser Group Transcript: Barclays 18th Annual Global Consumer Staples Conference 2025
A streamlined organization and focused innovation pipeline are driving faster execution and brand expansion. Cost savings and increased brand investment support growth, with emerging markets and power brands as key drivers. Supply chain upgrades and disciplined capital allocation underpin a positive financial outlook.
Metaguest.AI Begins Trading on OTCQB Venture Market, Provides Financing Update, and Announces Investor Forum on August 7
TORONTO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Metaguest.AI Incorporated (CSE: METG) (OTCQB:MGSTF) (“Metaguest” or the “Company”) an AI technology company transforming the hospitality sector through intel...
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...